Patient Search
KaCrole Higgins was diagnosed with breast cancer in 2020. “In May 2020, I found a lump in my breast. I cried. By June, it was diagnosed as breast cancer, triple positive, stage 1A. While getting this cancer diagnosis was devastating, it also became an opportunity. Suddenly, the cancer gave me clarity. It gave me clarity about what was important, what was good in my life, what was toxic in my life, and what I needed to do.” Click below to read more of KaCrole’s story |
If Landon Ryan had been diagnosed with bilateral retinoblastoma 10, 20 or 30 years ago, she might not be here today with nearly perfect vision.Thanks to recent improvements in the treatment for this rare form of cancer that almost exclusively affects children under the age of 5, the diagnosis had the power to change Landon’s life when she was 11 months old, but not to take it — or her eyesight. Click below to learn more about Landon and her story. https://momentum.vicc.org/2022/04/brighter-outlook/ |
Rigosertib Plus Pembrolizumab in Treating Patients with Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
Melanoma
Melanoma
This phase II clinical trial tests how well rigosertib plus pembrolizumab workings in treating patients with melanoma which cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to other places in the body (metastatic), and that has not responded to previous treatment with PD-1 or PD-L1 inhibitors (refractory). Rigosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may change the immune system to make immunotherapy more effective. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving rigosertib in combination with pembrolizumab may be more effective in treating patients with unresectable metastatic melanoma that has not responded to previous treatment with PD-1 or PD-L1 inhibitors than giving either drug alone.
Melanoma
II
Johnson, Douglas
NCT05764395
VICCMEL2218
REDUCE LAP II- A study to evaluate the Corvia Medical Inc IASD system II REDUCE Elevated Left Atrial Pressure in Patients with Hear Failure
Not Available
II
Gupta, Deepak
CRE-CHF0002
ALL-IN - Targeting Inflammation and Alloimmunity in Heart Transplant Recipients with Tocilizumab
Not Available
Schlendorf, Kelly
CRE-CHF0005
DEFINE-HT - DevelopmEnt of non-invasive cell-Free DNA to supplant INvasivE biopsy in Heart Transplantation
Not Available
III
Schlendorf, Kelly
CRE-CHF0010
CORDIO HearO - AN INTERNATIONAL, MULTICENTER, OBSERVATIONAL, SINGLE-ARM, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEAROTM SYSTEM
Not Available
Lindenfeld, Joann
CRE-CHF0011
LUX-Dx Heart Failure Sensors in an Insertable Cardiac Monitor System Clinical Study
Not Available
Lindenfeld, Joann
CRE-CHF0012
OCEANIC-AF - A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke
Not Available
III
Montgomery, Jay
CRE-ARR0018
Blood-based, Point-of-need Assessment of CAR-T Vector Load in DLBCL Patients Undergoing Axicabtagene Ciloleucel (axi-cel) Therapy: A Multi-Site Study
Lymphoma
Lymphoma
Lymphoma
N/A
Oluwole, Olalekan
VICC-IDCTT23426